Expression And Clinical Value Of HIF-1α,EPO And VEGF In Blood Of Patients With Central Retinal Vein Occlusion Complicated With Macular Edema

Objective :To explore the expression and clinical value of hypoxic inducible factor-1α(HIF-1α),erythropoietin(EPO)and vascular endothelial growth factor(VEGF)in the plasma of the patients with central retinal vein occlusion complicated with macular edema,and to explore a new method for the treatment of central retinal vein occlusion.Methods:A total of 50 patients with central retinal vein occlusion(CRVO)complicated with macular edema(ME)initially diagnosed in our hospital from October 2019 to December 2020 were selected and divided into ischemic group(group A)and non-ischemic group(group B)according to fundus fluorescence angiography.Lucentis injection was given in vitreous cavity according to 3+PRN regimen.At the same time,30 healthy people with matched sex and age were selected as the control group(group C).The serum levels of HIF-1α,EPO and VEGF in group A and B before injection and 2 weeks,1 month and 3 months after injection,and in group C were determined by enzymatic linked immunosorbent assay(ELISA).The changes of best corrected visual acuity(BCVA)and central macular thickness(CMT)before injection,2 weeks,1 month and 3 months after injection were observed in group A and group B.Results:1.Comparison of the general data and clinical indexes between the experimental group(group A+group B)and the control group(group C)showed no statistically significant differences in ages,genders and intraocular pressure(P>0.05);The differences of hypertension,fasting blood glucose,hyperlipidemia and hyperhomocysteinemia were statistically significant between the two groups(P<0.05).2.The expression levels of serum HIF-1α,EPO and VEGF in groups A and B were significantly higher than those in group C(P<0.05),and the levels of serum HIF-1α,EPO and VEGF in group A were higher than those in group B(P<0.05)3.At 2 weeks,1 month and 3 months after injection,the levels of serum HIF-1α,EPO and VEGF in groups A and B decreased significantly compared with before injection,and the differences were statistically significant(P<0.05).4.At 2 weeks,1 month and 3 months after injection,BCVA in group A and group B was significantly higher than that before injection;CMT was significantly thinner than before treatment,and the differences were statistically significant.(P<0.05).Conclusion:1.Serum HIF-1α,EPO and VEGF were highly expressed in patients with CRVO complicated with ME,and increased significantly with the severity of the disease,suggesting that HIF-1α,EPO and VEGF may play an important role in the occurrence and development of CRVO.2.Intravitreal injection of Lucentis can significantly reduce serum levels of HIF-1α,EPO and VEGF in CRVO patients with ME,improve visual acuity,eliminate macular edema,and improve the quality of life of patients.